Malaria
Conditions
Interventions
Chloroquine plus Primaquine treatment
Sponsors
Dilla University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged more than 6 months with confirmed Plasmodium vivax mono-infection by microscopy Parasite density =250 asexual parasites/µL Living within 10 km radius of the study health facility Willing to participate and provide written informed consent (or parental consent for minors) Able and willing to complete 28-day follow-up visits
Exclusion criteria
Exclusion criteria: Severe or complicated malaria Hemoglobin level <5 g/dL Use of antimalarial or antibiotics with antimalarial activity within the previous 14 days Pregnant women Breastfeeding mothers with infants =6 months Known hypersensitivity to chloroquine or primaquine Planned relocation from study area during follow-up period History of hemolysis or G6PD-related contraindications (if you assessed/considered clinically)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adequate clinical and parasitological response (ACPR) of Plasmodium vivax infection following chloroquine plus primaquine treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Parasite clearance rate on day 3 following treatment Fever clearance rate on day 3 following treatment Hemoglobin change between day 0 and day 28 Recurrence or treatment failure within 28 days of follow-up Incidence of adverse drug reactions during follow-up period | — |
Countries
Ethiopia
Contacts
Public ContactYabibal Gebeyehu
Medical Pediatrics
Outcome results
None listed